产品说明
应用
bPiDl hydrate may be used to study nicotinic receptor-mediated signaling.
包装
10 mg in glass bottle
生化/生理作用
bPiDI is an α6β2-specific antagonist that inhibits nicotine-evoked and endogenous dopamine release from rat striatal slices (IC50 = 150 nM, Imax = 55%). bPiDI treatment decreases nicotine self-administration, and nicotine-induced locomotor activity in rats.
特点和优势
This compound is featured on the Acetylcholine Receptors (Nicotinic) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
基本信息
经验(实验)分子式 | C22H34I2N2 · xH2O |
分子量 | 580.33 (anhydrous basis) |
MDL编号 | MFCD21608520 |
PubChem化学物质编号 | 329825211 |
NACRES | NA.77 |
产品性质
质量水平 | 100 |
测定 | ≥98% (HPLC) |
形式 | powder |
颜色 | white to tan |
溶解性 | H2O: ≥10 mg/mL |
储存温度 | 2-8℃ |
SMILES string | O.[I-].[I-].Cc1ccc[n+](CCCCCCCCCC[n+]2cccc(C)c2)c1 |
InChI | 1S/C22H34N2.2HI.H2O/c1-21-13-11-17-23(19-21)15-9-7-5-3-4-6-8-10-16-24-18-12-14-22(2)20-24;;;/h11-14,17-20H,3-10,15-16H2,1-2H3;2*1H;1H2/q+2;;;/p-2 |
InChI key | ILAREMIWZYIULF-UHFFFAOYSA-L |
安全信息
储存分类代码 | 13 - Non Combustible Solids |
WGK | WGK 3 |
闪点(F) | Not applicable |
闪点(C) | Not applicable |